Kirby Seminar - Dr David Boettiger - "HIV/HCV co-infection in the Asia-Pacific region."

Image - Kirby Seminar - Dr David Boettiger - "HIV/HCV co-infection in the Asia-Pacific region."
Event type: 
Event date: 
Tuesday, 18 October 2016 - 1:00pm to 2:00pm

Level 6, Seminar Room, Wallace Wurth Building
UNSW Australia Sydney NSW 2052

Contact for inquiries: 
Rata Joseph, +61 (0)2 9385 0900 or
Booking deadline: 

The Kirby Institute is pleased to present: 

Dr David Boettiger – Research Fellow – Biostatistics and Database Program, Kirby Institute
"HIV/HCV co-infection in the Asia-Pacific region."
While options for treating HCV have been around for decades, they are not readily accessible in many parts of Asia. I will discuss some of the ongoing work being conducted by TREAT Asia to address this shortfall, including the push to enhance regional access to generic DAAs manufactured in India. The second part of my talk will focus on the HIV/HCV co-infected population in Australia, where DAAs have recently been PBS approved with very little restriction on prescribing. I will present results from an ACCESS analysis investigating HCV testing rates and HCV incidence in HIV-positive people and plans to use this data for modelling the best approach to eliminate HCV transmission among the HIV population.  
David is a biostatistician working in the Biostatistics and Databases Program. He was recently awarded his PhD which was based on observational HIV cohort data from Asia. In addition to his work with TAHOD and TApHOD, he leads the data management and statistical analysis for a TAHOD sub-study evaluating interferon-based treatment in the HCV/HIV co-infected population. In January 2016, David was also awarded a Gilead research grant to investigate the use of DAAs in Australia’s HIV/HCV co-infected population.